CBS 2019
CBSMD教育中心
中 文

DAPT Duration

Abstract

Recommended Article

Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI

Original Research2020 May 5;141(18):1463-1476.

JOURNAL:Circulation. Article Link

Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure

JA Chirinos, L Zhao, Y Jia et al. Keywords: apolipoproteins M; heart failure; lipoproteins, HDL; sphingosine-1-phosphate; survival.

Full Text PDF